Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
TVM Capital Life Science, established in 1983 as a spin-off from Techno Venture Management, is based in Munich, Germany, with an office in Montreal, Canada. The firm has $900 million in assets under management and has focused exclusively on life sciences since 2012. Their team specializes in supporting companies to become leaders in their market segments.
TVM Capital Life Science invests in pre-seed to Series C stages, targeting biotech, healthcare, and digital health sectors. Their dual-pronged strategy includes financing innovative early-stage therapeutics through a single-asset company approach and investing in differentiated commercial-stage medical technologies and diagnostics. They prioritize areas with high unmet medical needs, including oncology and immunology.
Notable portfolio companies include Aurka Pharma Inc., acquired by Eli Lilly shortly after TVM's investment; CoLucid Pharmaceuticals, which achieved a successful IPO and was acquired by Eli Lilly for $960 million; and Acanthas Pharma, Inc., developed a small molecule targeting cancer mutations and was also acquired by Eli Lilly.
Email info@tvm-capital.com with your deck to pitch TVM Capital Life Science.
Yes, TVM Capital Life Science often leads investment rounds, particularly in early-stage therapeutics.
The firm actively participates in follow-on investments to support portfolio companies as they grow and achieve milestones.
TVM Capital Life Science manages approximately $900 million in assets under management.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.